Photography exhibition highlights lives of people with Chronic Kidney Disease – Yahoo Finance

Photography exhibition highlights lives of people with Chronic Kidney Disease
Quanta sponsors private viewing of Survivors: Life Unfiltered to raise awareness of chronic kidney disease
ALCESTER, England, 28 October 2021: Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”, a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system), is proud to sponsor a new photography exhibition Survivors: Life Unfiltered, running from 26 October to 7 November 2021, at the OXO Gallery in London.
This exhibition was created by award winning photographer Richard Booth and the Company’s patient advocate, Maddy Warren, to raise public awareness about the critical importance of kidney health and to shine a light on the real lives and experiences of those who live with kidney disease, dialysis or a transplant. The exhibition tells the stories of people from all walks of life around the UK, using diptych images to show both sides of what it’s like to exist day to day with a life-limiting, hidden condition. The inspiring stories cover topics as diverse as facing mortality, mental health, body image, gratitude, survivor’s guilt, silver linings and reconciling with a ‘new normal’.

Quanta recently published a UK Dialysis Patient Experience Survey which highlighted the wide variance in care experienced by UK dialysis patients, as well as challenges faced in accessing self-care and home haemodialysis. Quanta is dedicated to empowering better experiences for dialysis patients and enabling access to the highest-quality shared and self-care therapies, by putting people, including those featured in this exhibition, at the heart of our approach. The full survey can be viewed here.
Quanta CEO, John E. Milad, comments: “Quanta is committed to making kidney care more accessible to every patient. Powerful events and exhibitions such as Survivors: Life Unfiltered are instrumental in growing awareness and improving the lives of people living with this life-limiting condition. We are honoured to play a role in this important initiative”.
Event organiser, Quanta Patient Advocate, andQueen of Dialysis’, Maddy Warren adds: “We encourage everyone to visit the exhibition, showcasing Richard Booth’s beautiful photography alongside emotive personal stories, which is running until 7 November. Thanks to event sponsor Quanta and co-sponsors Kidney Care UK and Kidney Research UK, who made this insightful and thought-provoking exhibition possible.”
To find out more about Survivors: Life Unfiltered, please click here.
Images from the private launch event are available upon request.
-Ends-
For more information about Quanta, please contact:

Quanta

David Bond

Marketing Communications and Brand Manager

T: 07961 471 833

E: [email protected]

Consilium Strategic Communications

Amber Fennell / Matthew Neal / Lindsey Neville
T: +44 (0)203 709 5708

E: [email protected]
About Chronic Kidney Disease
Chronic Kidney Disease (CKD) is often known as a silent killer and commonly shows no symptoms until a very late, critical stage. More people now die of it than of several types of cancer and once diagnosed they undergo treatment for life, and there is no cure. It affects around 3 million people in the UK, more than the number currently living with cancer, and the BAME community is disproportionately affected. It became rapidly apparent at the start of the pandemic that many people in intensive care with Covid-19 also developed Acute Kidney Injury requiring life sustaining dialysis.
About Haemodialysis
Haemodialysis is a life sustaining treatment for patients with kidney failure to help normalise blood chemistry and remove waste products and excess fluids.
About Quanta and SC+
Quanta Dialysis Technologies is reinventing kidney care to be more accessible to every patient in every setting with its SC+ haemodialysis system. With performance comparable to larger, traditional machines, SC+ is a modular and powerful solution that provides the clinical versatility needed to deliver dialysis care across multiple settings. As a portable system with an intuitive simple user interface, SC+ is designed to be operated by a broad range of users to bring dialysis directly to patients.
SC+ is commercially available in the United Kingdom for home and hospital use and in the United States is FDA-cleared (K210661) for use in chronic and acute care settings.
For more information, please visit: www.quantadt.com
About Kidney Care UK
Kidney Care UK are the UK’s leading kidney patient support charity, providing practical, financial and emotional support for kidney patients and their families, and campaigning to improve care services nationally. They help to improve the quality of life for everybody affected by kidney disease.
For more information, please visit https://www.kidneycareuk.org/
About Kidney Research UK
Kidney Research UK is the leading kidney research charity in the UK and nothing is going to stop us in our urgent mission to end kidney disease. We’re here to be heard, to make a difference, to change the future. This is a disease that ruins and destroys lives. It must be stopped. Our vision is the day when everyone lives free from kidney disease.
For more information, please visit https://kidneyresearchuk.org/
Attachments
Survivors-Asif Ali-©Richard Booth (1)
A3783-CKD-Jay Andrews32770 (1)
A3783-CKD-Maddy_Warren-0062v3

European Central Bank President Christine Lagarde acknowledged on Thursday that inflation will be high for even longer but pushed back against market bets that price pressures would trigger an interest rate hike as soon as next year. With central banks around the world signalling tighter policy amid rising prices, Lagarde said the ECB had done much "soul-searching" over its stance but concluded that inflation was still temporary, so a policy response would be premature. "We talked about inflation, inflation, inflation," Lagarde told a news conference following the ECB's policy meeting.
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven…
BERLIN (Reuters) -Beiersdorf expects a recovery in travel retail and demand for sun care products to boost sales in 2022, when the Nivea maker also hopes for a rebound in sales of adhesives to the automotive industry. The German company plans to offset rising costs of raw materials by increasing prices and cutting costs, targeting a small increase in its operating margin in 2022, finance chief Astrid Hermann told analysts on Thursday. Beiersdorf made the forecasts after reporting third-quarter sales rose an underlying 4.3% to 1.9 billion euros ($2.2 billion), shy of some analysts' forecasts.
(Bloomberg) — Saudi Basic Industries Corp., the world’s biggest chemicals maker by market value, saw profit fall as rising feedstock costs lowered its margins.Most Read from BloombergA Deep Dive Into Squid Game's World of InequalityMeet Six People Fighting Water Scarcity Across the GlobeThe Terrifying Rise of Haunted TourismCan a New Mayor Fix Seattle’s Downtown?In Minneapolis Election, the Future of Policing Is at StakeThe stock dropped as much as 3.3%, the most since April, before paring loss
Cigarette smoking is the leading cause in preventable disease and death in the U.S., according to the CDC.
(Bloomberg) — Merck & Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much as $7 billion in global sales through 2022, according to the drugmaker. Most Read from BloombergA Deep Dive Into Squid Game's World of InequalityCan a New Mayor Fix Seattle’s Downtown?The Terrifying Rise of Haunted TourismIn Minneapolis Election, the Future of Policing Is at StakeMeet Six People Fighting Water Scarcity Across the GlobeThe figure includes up to $1 billion in revenue this year if th
Prescription drug prices have become a key target of criticism by those calling for reforms to the U.S. health care system.
With that in mind, let's look at two healthcare stocks that have performed poorly over the past year but have a chance to bounce back big: Gilead Sciences (NASDAQ: GILD) and Incyte (NASDAQ: INCY). Biotech giant Gilead Sciences is still feeling the aftereffects of a regulatory setback related to filgotinib, its potential medicine for rheumatoid arthritis. The company hoped that it would become a blockbuster product, but the U.S. Food and Drug Administration (FDA) had other plans.
California expects to have more than 1.2 million doses of Pfizer’s COVID-19 vaccine available for children ages 5-11 to get vaccinated the first week once the shots are cleared for the age group, the state’s epidemiologist said on Wednesday. KCRA 3's Brandi Cummings reports on the latest developments.
With sagging sales and lackluster data in a recent trial, what does the future hold for shareholders?
Cortexyme Inc (NASDAQ: CRTX) shares are trading lower after the company's Phase 2/3 GAIN trial did not meet its co-primary endpoints. Cortexyme says they will present the additional top-line results from the GAIN Trial at the upcoming 14th Clinical Trials on Alzheimer's Disease (CTAD 2021) conference on Thursday, November 11 at 11:35 a.m. ET in Boston, Massachusetts. Cortexyme's CTAD 2021 presentation will be available on the company's Investor Relations website at ir.cortexyme.com. See Also: Wh
Most of us saw COVID vaccinations as a light at the end of the tunnel when they first arrived in the U.S., but over the past year, the pandemic has persisted amid the rise of the fast-spreading Delta variant and a significant drop in vaccination rates. Now, health experts and officials are exploring new options to try to stop the spread of COVID for good, like vaccine mandates, reinstated mask restrictions, and booster shots. But some experts say they're holding out hope that the end of the pand
(Reuters) -Merck & Co Inc on Thursday said its experimental COVID-19 drug could bring in between $5 billion and $7 billion in sales through the end of next year, assuming it gains U.S. authorization in December. Merck's shares rose more than 4% to $84.88 in early trading. The antiviral drug, molnupiravir, has been closely watched since Merck earlier this month reported data https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-covid-19-pill-cuts-risk-death-hospitalization-by-50-study-2021-10-01 that showed it could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19 when given early in the illness.
A clinical trial showed that patients with the greatest reduction in a specific bacterium saw the greatest cognitive benefit from the South San Francisco company's drug, but the trail failed to meet its primary targets.
The move suggests that the White House is confident that the CDC won't limit the rollout of the pediatric vaccine to children at high risk of serious illness.
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus. Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies. “If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available.
Is Pfizer stock a buy after FDA advisors said the benefits outweigh the risks of Covid shots in children age 5-11? Is PFE stock a buy now?
The Delta coronavirus variant can transmit easily from vaccinated people to their household contacts, a British study found on Thursday, although contacts were less likely to get infected if they were vaccinated themselves. The Imperial College London study illustrates how the highly transmissible Delta variant can spread even in a vaccinated population. The researchers underlined that did not weaken the argument for vaccination as the best way of reducing serious illness from COVID-19 and said booster shots were required.
Especially as they voyage back home, we wish the Arby family the best.
A cheap, widely available antidepressant that has been prescribed for almost three decades could help reduce coronavirus hospital admissions by 32 per cent, according to a large clinical trial.

source